US Edition
Published • loading... • Updated
Belgian drugmaker UCB to invest $2B in suburban Atlanta plant, adding 330 jobs
UCB's $2 billion investment in Gwinnett County will create 330 permanent jobs and generate $5 billion in economic impact, strengthening biologics manufacturing in the U.S.
- On Tuesday, Belgium-based biopharmaceutical firm UCB announced a $2 billion investment to build a new biologics manufacturing campus in Gwinnett County, Georgia, within the Rowen innovation district.
- Strengthening its global biologics manufacturing network, UCB selected the Rowen site to support growing demand across its portfolio while building on its existing North American headquarters in Smyrna, Georgia.
- The project is expected to generate approximately $5 billion in total economic impact, with Gwinnett County committing $174 million in incentives to support more than 330 permanent highly skilled jobs.
- Governor Brian Kemp called the investment a "significant milestone," while UCB CEO Jean-Christophe Tellier stated the decision reflects "confidence in UCB's long-term growth and our deep-rooted commitment to the United States."
- Construction on the 460,000-square-foot facility is expected to take six to seven years, positioning the Rowen Foundation's campus as a hub for future life sciences collaboration in the region.
Insights by Ground AI
51 Articles
51 Articles
UCB Selects Rowen for $2B Biopharmaceutical Manufacturing Campus
First tenant milestone validates Rowen's innovation community model and signals the start of a new life sciences hub in Gwinnett CountyGWINNETT COUNTY, Ga., March 24, 2026 /PRNewswire/ -- The State of
·New York, United States
Read Full Article
Coverage Details
Total News Sources51
Leaning Left8Leaning Right9Center15Last UpdatedBias Distribution47% Center
Bias Distribution
- 47% of the sources are Center
47% Center
L 25%
C 47%
R 28%
Factuality
To view factuality data please Upgrade to Premium
